IT systems · Practical guide

Validating Veeva RIM: tracing the correct market-specific status through submission

A new document version may apply in one market before another. In Veeva RIM, follow product identity, document version, procedure status and the evidence for the decision. A two-market example shows why complete records and successful transmission alone cannot establish correct regulatory use. Consider publishing, cloud changes, responsibilities and archive boundaries together.

Table of contents

At a glance

How do you assess Veeva RIM for its intended use?

Define the Veeva RIM applications and regulatory workflow in scope. Test product, application and market relationships, approved document versions, Content Plan and actual output. Link technical results and gateway responses to the correct submission version. The authoritative market status needs evidence of its own decision. Assess the coverage of supplier and existing evidence against the real use.

  • RIM, safety, and clinical data collection represent distinct application areas.
  • Application, document, and market relationships must be technically consistent.
  • Latest for Authoring is not a blanket proof of official authorization.
  • Technical inspection, submission, and professional approval remain separate.

1. Define the RIM within the specific marketing authorization process

Veeva RIM integrates applications for regulatory submissions, submission content, publishing, and archiving on a cloud platform. It should be distinguished from Veeva Safety and clinical data capture. A study report within the regulatory dossier does not make RIM the system in which original study data were collected. Similarly, a regulatory change does not constitute a single adverse event.

For the evaluation of suitability, it is important to understand which decisions are based on what information. Should RIM indicate which document version is materially relevant in a market context? Is a change being planned, a dossier being compiled, or a regulatory response being tracked? Define these tasks—including their interfaces—clearly. Simply being part of the pharmaceutical industry does not determine the scope of evidence required.

Annex 11 should be considered in the context of human medicinal product GMP, for example when a regulatory communication supports a controlled process. This does not imply a blanket application of GMP requirements to every RIM function. FDA requirements for electronic records must be evaluated based on the actual scope of use. Manufacturer configuration, technical submission review, and scientific approval decisions remain distinct matters. No product name automatically confers a GAMP category, signature obligation, or official recognition.

Sources: [1] [12] [11]

Further reading:

2. Describe the actually licensed scope of RIM.

The Veeva overview distinguishes between Registrations, Submissions, Submissions Publishing, and Submissions Archive. They share a common data model but serve different functions. A Registrations engagement does not verify that Publishing is licensed and properly configured. Capture details of your vault applications, activated features, data connections, and user responsibilities.

Here, the concrete release anchor points are the published details for 26R2 with distribution deadlines on 31 July and 7 August 2026. Additionally, the General Release Support becomes available on 6 October 2026. This does not represent a confirmed version status for your tenant. Functions from a Limited Release will not be unverifiedly adopted as general availability.

The following table links applications to an example usage scenario. It serves as a standalone planning aid and is not a complete license or data model description. Pay particular attention to whether a task is performed in Veeva, in an external solution, or manually. These transitions often generate more audit work than the number of visible modules.

Example: Assignment for a product change process
ApplicationTaskDecisive evidence
Registrations Trace the applicable version for each market Correct product, marketing authorization, and market alignment
Submissions Prepare documents for the change. Released versions and corresponding scope
Submissions Publishing Create submission from the content plan Correct release and associated technical test platform
Submissions Archive Retrieve the submitted version and correspondence Auditable history and correct assignment
External Connection Forward regulatory decision Equivalent meaning in the process in the receiving process

Sources: [1] [7] [3] [6]

3. Treat object relationships as a professional judgment

Application, Regulatory Objective, and Submission are not interchangeable labels. Veevas Submission Wizard supports the selection of relationships from the Application and their transfer to Submission or Regulatory Objective. For certain updates, the appropriate registration linkages are also important. However, the software can only function with the selected and maintained context.

Therefore, define which product, market, and change subject are interrelated. A copied data record may formally be complete yet still include a non-affected marketing authorization or inadvertently omit a relevant one. Verify a correct reference, an intentionally mismatched market, and a missing relationship. The required scope is derived from the professionally defined scope of change, not from the system-generated output.

For existing data, it must be clarified which source is primary and who determines inconsistencies. When relationships are transferred from another system, their meaning must be preserved. A technical import based solely on the expected number of rows is insufficient if the same rows are incorrectly linked to the wrong application. The intended assignment must be clearly documented to enable Regulatory Affairs and IT to identify the same errors.

Sources: [2] [1]

4. Content Plan, Document Version, and Publishing Release to be linked

In Submissions Publishing, content documents are linked to submission filings. Veeva also describes Continuous Publishing, which enables the inclusion of relevant changes to source documents or links within the output. The actual content that is published depends, among other factors, on the selected source and rendition settings, as well as the configuration.

For the demonstration, you should independently determine a validated source and the expected output. Verify that the correct version appears at the correct location and that the required references function properly. A newer draft with a similar name must not inadvertently replace the document designated for submission. If a editable source file instead of its view is required, that selection must be unambiguous.

Additionally, investigate what occurs when a change occurs during preparation. Is the previously reviewed package status still identifiable? Is the output regenerated, and is the review updated accordingly? The product functionality for tracking changes does not automatically address these operational closure questions. Define which version is ultimately reviewed, submitted, and later verified as issued. For external sources, the version and metadata transfer must be considered in the same context.

Sources: [3] [8]

5. Example: Two markets, two allowable version states

This model is not a completed Veeva test. A prototype product has the document statuses S1, B1, and P1 in both Market A and Market B. For the change from S1 to S2, the following example assumption explicitly applies: the new status becomes effective only after the required positive decision has been made in each respective market. This is not a general rule applicable to all change procedures. S2 has been submitted in both markets; however, a required decision is only available for Market A. For Market B, S1 remains effective.

The predetermined target still contains six market document assignments: three for A and three for B. Five of these show version 1 and one for version 2. Two submissions therefore do not result in two new market positions released. Even a mere number of six records would not detect the error if B were wrongly assigned to S2.

The Veevas Active Dossier is configuration- and metadata-dependent. The field "Latest for Authoring" follows the document hierarchy within a defined Application-, Country-, and Product context. It is therefore not used as evidence of a regulatory decision. Review, within your own structure, which information actually addresses the specific technical question. Prior to any error case, the same relationships, document versions, and decision records are established; subsequently, a market reference or decision status is intentionally modified.

Expected results for the authoritative states in the example model
MarketDocumentSituationExpected critical point of reference
A S S2 submitted; required decision is available S2
A B Unchanged B1
A P Unchanged P1
B S S2 submitted; required decision still open S1
B B Unchanged B1
B P Unchanged P1

Sources: [5] [2]

6. Assess technical results, including checks that did not run

Veeva distinguishes among Submission Validation Results, including Pass, Failure, Not Executed, and Internal Error. These states are not equivalent. A validation that was not executed must not be implicitly treated as a successful check and included in the final release assessment without proper consideration. Define the rules applicable to the specific submission and specify how unexecuted or erroneous executions should be handled.

The criteria set must align with region and format. The EU eCTD Guidance separates technical evaluation from content assessment and limits what technical criteria can establish regarding correct metadata. Therefore, a flawless report cannot substitute for an incorrect market assignment derived from the example itself. Supplement the technical review against the approved scope.

A specific 26R2 note is critical for change evaluation: If the Validation Criteria version is modified and saved, Veeva triggers an automatic on-demand review when Continuous Publishing is enabled. Verify this condition within your own setup. A different switch state or a report prior to the change does not constitute the same validation evidence. Ensure clarity in the relationship between criteria, reviewed output, and the resulting decision.

Sources: [4] [3] [7] [8]

7. Shipping, technical response, and decision-making to be separated

Veeva defines gateway profiles for specific US and EU submissions. Profiles must be properly configured and activated, including appropriate regulatory authority access and configuration data. The EMA eCTD connectivity is described in the documented centralized procedure scope. This does not constitute general support for all submission pathways, accounts, or regional procedures.

Verify, using appropriate test scenarios, that the package, recipient, and response are consistent and aligned. An issued dataset must not inadvertently be linked to a different market or an incorrect application. Define the handling of missing, negative, or delayed feedback. A subsequent technical reattempt must not obscure the original process to the extent that it becomes unclear later which data was actually transmitted.

The EMA refers to automated notification as a technical validation notification. It is not a general substantive marketing authorization decision. Therefore, in the RIM process, it is essential to clearly distinguish whether a particular action has been prepared, sent, technically accepted, or professionally decided. The own two-market example still requires, for S2 in Market B, the relevant decision documentation. A successful dispatch alone does not alter this requirement.

Sources: [6] [10] [8]

8. Rights and subsequent readability of the required evidence to be aligned

Responsibility holders must be able to determine who is authorized to make professional assignments, document assignments, or status changes. When assessing this, consider not only standard processing procedures but also administrative capabilities and the controlled correction pathway. A misassigned country designation must be correctable without rendering the previously relevant status and its rationale incomprehensible.

The assistance for Submission Validation Results describes a dedicated archiving job: Under the conditions specified, results are transferred into a package containing XML and other files; successfully archived result datasets are then deleted. This product logic does not constitute a legal retention period. Verify that the reports required for your decision remain clearly accessible later in the context of submission, version, and criteria.

For GMP-related records, protection, relationships, and controlled corrections must be considered within the applicable documentation scope. For FDA records, the evaluation shall follow the relevant fundamental requirements and the specific electronic usage. Explicitly define retention period, protection, and authorized correction pathways. Additionally, verify that an internal release action actually fulfills the required electronic signature for the respective process.

Sources: [4] [13] [12] [11]

Further reading:

9. Release, change of criteria, and migration to the own process flow

A cloud platform does not exempt the user from understanding relevant changes. Start by identifying the affected workflow: does the data linkage, publishing rule, result presentation, or connection to another application change? The 26R2 release notes, for example, include RIM and connection updates. Not every described enhancement is active in every Vault or equally critical for each process.

Evaluate supplier documentation and existing evidence based on their actual scope, version, configuration, and environment. A delivery package may cover more or less than the actual intended use; blanket assumptions about only standard functions are not sufficient. Derive remaining assessments from specific gaps and risks. A complete re-development of all tests is no more automatically required than an unverified waiver.

During a migration, object relationships, versions, and business status meanings are particularly important. Verify known market statuses against an independent source, including both an open and a closed procedure. For a transition to eCTD 4.0, technical product support and regulatory process maturity must align. The EU-described transition distinguishes new applications from existing product life cycles; a simple format option in the tool does not determine suitability.

Sources: [7] [5] [9] [12]

10. Start with a clear required and available point of contact

Before starting, a representative product change case with the affected markets and relevant evidence should be available. Regulatory Affairs determines the importance of decisions and status information. Document managers explain the released content, the Vault administration data model and configuration, IT the connections and operating limits. QA is included according to the actual quality scope concerned.

The effort primarily depends on data quality, the number of different processes, historical inventories, system configuration, and external transitions. Numerous similar submissions may require less clarification than a few exceptional cases with unclear relationships. During an implementation, the intended state is defined prior to configuration; in the existing environment, the actual workflow must first be compared against existing rules and data.

The checklist enables formulating a specific task assignment rather than a general product inspection. Open questions regarding license, version, or delivery documentation are explicitly documented. Without appropriate test capabilities, claims of efficacy remain unsubstantiated; they are not replaced by a functional description.

  • List the RIM applications used, current configuration status, and responsibilities assigned.
  • Define product, application, markets, and regulatory scope of change.
  • Provide approved document versions and expected country statuses.
  • Capture content plan, format, versioning criteria, and output assignment.
  • Separate test profiles from actual data submission clearly.
  • Prepare open, technically acceptable, and professionally justified cases.
  • Assign supplier documentation, migration data, and retention purposes in a traceable manner.

Sources: [1] [2] [3]

Project experience and collaboration

Trace the submission version from the relevant market through to the response

Regulatory Affairs selects a submission and links its product and market to the document versions used. We follow the content plan, generated output and available responses. This shows whether a link is missing or the change process itself needs revision. For a new RIM structure, your owners identify with us which information substantiates the regulatory status in each market. Technical transmission and the authority's decision remain distinguishable.

Frequently asked questions about Veeva RIM

Is Veeva RIM the same as Veeva Safety?

No. RIM manages regulatory information, submission contents, publishing, and archiving. Safety is a separate product area dedicated to safety processes. Data connections between applications may exist; the specific configuration of such connections must be independently verified. A shared platform name does not permit unverified transfer of functions or evidence from a safety case management process to a regulatory dossier process.

Sources: [1]

Do we need to validate all RIM applications jointly?

The scope is determined by the actual applications, functions, and dependencies in use. Registration alone does not automatically imply publishing or the availability of any connections. Specify which task is performed where and which data is transferred. Relevant common foundations may be jointly evaluated; however, different professional judgments still require appropriate requirements and supporting evidence.

Sources: [1] [3] [12]

Which Veeva release do the statements refer to?

The specific release anchor is 26R2, with published delivery dates in July and August 2026. Additionally, the general release support is based on the source status. Tenant environments, licensed applications, and activated configurations are not verified. Release notes from limited releases are not considered equivalent to general availability; confirm the actually relevant status for your intended use.

Sources: [7]

Why are application and market relationships so important?

You determine the specific subject matter to which a submission or update relates. The Submission Wizard supports controlled selection and acceptance of relationships, but does not automatically recognize your approved scope of changes. Therefore, independently verify a foreign market and the absence of a relationship. Complete fields or a plausible number of records alone do not constitute valid assignment.

Sources: [2]

Is the latest version for authoring always the currently approved version?

No. Veeva derives "Latest for Authoring" from the document hierarchy in the respective Application-, Country-, and Product context. The technical question regarding the relevant market status additionally requires the appropriate procedural and decision-making reference. In the example of this article, S2 may already be available for further processing, while in Market B, S1 may still be relevant.

Sources: [5]

What does it mean when a technical check did not run?

"Not Executed is a distinct result status and must not be treated as Pass. Investigate the root cause, relevance of the criterion, and the necessary next step. Any Internal Error or open failure report must be assigned to the reviewed output. A report documents the performed technical checks, not automatically the complete professional correctness of the dossier."

Sources: [4] [8]

Does a change in the criteria version always trigger a new validation?

The 26R2 Release Specification identifies a specific condition: when a modified Validation Criteria version is saved, an on-demand review is triggered if Continuous Publishing is enabled. Carefully evaluate this state within your own implementation. Do not unverifiedly transfer this behavior to other profiles, configurations, or a disabled publishing process.

Sources: [7] [3]

Does a gateway response already constitute official regulatory approval?

No. A technical response confirms the respective transmission step or technical inspection status. It does not replace any other required business decision. Clearly assign the response, package, and procedure, and manage missing or negative feedback in a controlled manner.

Sources: [6] [10] [8]

Who are the personnel and documents required before project start?

The following scope, affected markets, approved documents, object relationships, and a clear as-builts state are required. Regulatory Affairs, document owners, Vault administration, IT, and potentially QA must participate. Key drivers of effort include data cleansing, historical relationships, special procedures, and external linkages. Without these information elements, generic time or cost commitments cannot be reliably justified.

Sources: [1] [2]

Does the archiving job also fulfill our entire retention obligation?

No. It describes a specific internal product-level handling of validation results. You must assess which records are required for your process type and whether they, including their interrelationships, are later understandable and available. Technical job conditions are not general legal deadlines. A pre-existing ZIP package is only an appropriate evidence when its contents are comprehensible for the intended purpose.

Sources: [4] [11] [13]

Sources and review date

Source date: 6 October 2026. General release support and explicit release anchor 26R2; no confirmed tenant or license status. Product mechanics remain bound to the described configuration. Tables and market standings are standalone target models.

  1. Veeva: RIM overview
  2. Veeva: Submission Wizard
  3. Veeva: Working with Submissions Publishing
  4. Veeva: Working with Submission Validation Results
  5. Veeva: Information on Active Dossiers
  6. Veeva: Configuring Gateway Integration
  7. Veeva: What’s New in 26R2
  8. EMA/eSubmission Expert Group: Harmonised Technical Guidance for eCTD Submissions in the EU
  9. EMA: eCTD v4.0 implementation
  10. EMA: eSubmission Gateway and Web Client
  11. FDA: Part 11 Scope and Application
  12. European Commission: EU GMP Annex 11 Computerised Systems
  13. European Commission: EU GMP Chapter 4 Documentation

Sources checked: .

Daniel Herrmann, Daniel Herrmann Consulting

Daniel Herrmann Consulting

Regulatory data references and evidence clearly linked

We support you in professionally defining the RIM usage scope and verifying the key relationships between documents, markets, and submission authorities.

  • Cloud and SaaS validation →

    Maintain the validated state of cloud and SaaS systems as suppliers issue new versions. We define the boundary between your responsibilities and the supplier’s and agree how each release will be assessed.

Send a project enquiry Customer testimonials →